This data suggests that targeting of epithelial CXCR4 may be an appropriate therapeutic strategy for pulmonary fibrosis, particularly in patients with IPF and potentially those with non-IPF ILD. This evidence concerns the gene CXCR4 and pulmonary fibrosis.